-
1
-
-
34247512663
-
International Agency for Research on Cancer
-
World Health Organization, Lyon: IARC Press
-
World Health Organization. International Agency for Research on Cancer. World Cancer Report. Lyon: IARC Press, 2008.
-
(2008)
World Cancer Report
-
-
-
2
-
-
77955635233
-
Cancer statistics, 2010
-
Epub 2010/07/09
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 60(5):277-300. Epub 2010/07/09.
-
CA Cancer J Clin
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
43449127502
-
Prostate cancer
-
Epub, 2008/05/20
-
Damber JE, Aus G. Prostate cancer. Lancet. 2008;371(9625):1710-21. Epub 2008/05/20. http://dx.doi.org/10.1016/S0140-6736(08)60729-1.
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1710-1721
-
-
Damber, J.E.1
Aus, G.2
-
4
-
-
3242813926
-
International trends in prostate-cancer mortality: The decrease is continuing and spreading
-
Epub 2004/04/20
-
Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15(3):237-41. Epub 2004/04/20. http://dx.doi.org/10.1023/B:CACO.0000024212.66334.26.
-
(2004)
Cancer Causes Control
, vol.15
, Issue.3
, pp. 237-241
-
-
Baade, P.D.1
Coory, M.D.2
Aitken, J.F.3
-
5
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
Epub 2007/02/09
-
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-92. Epub 2007/02/09.
-
(2007)
Ann Oncol
, vol.18
, Issue.3
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
Colombet, M.5
Boyle, P.6
-
6
-
-
80052335168
-
-
Brasil. Ministério da Saúde, Estimativa, Incidência de Câncer no Brasil. Available at, (Accessed on 10/7/10)
-
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2010: Incidência de Câncer no Brasil. Available at http://www.inca.gov.br/estimativa/2010/ (Accessed on 10/7/10).
-
(2010)
Instituto Nacional De Câncer
-
-
-
7
-
-
25444446079
-
Advances in prostate cancer chemotherapy: A new era begins
-
quiz, Epub 2005/, 09/17
-
Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55(5):300-18; quiz 23-5. Epub 2005/09/17. http://dx.doi.org/10.3322/canjclin.55.5.300.
-
(2005)
CA Cancer J Clin
, vol.55
, Issue.5
, pp. 300-318
-
-
Pienta, K.J.1
Smith, D.C.2
-
8
-
-
0033952191
-
Clinical states in prostate cancer: Toward a dynamic model of disease progression
-
Epub 2000/03/04
-
Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55(3):323-7. Epub 2000/03/04. http://dx.doi.org/10.1016/S0090-4295(99)00471-9.
-
(2000)
Urology
, vol.55
, Issue.3
, pp. 323-327
-
-
Scher, H.I.1
Heller, G.2
-
9
-
-
0036112592
-
The current state of hormonal therapy for prostate cancer
-
Epub 2002/05/23
-
Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52(3):154-79. Epub 2002/05/23. http://dx.doi.org/10.3322/canjclin.52.3.154.
-
(2002)
CA Cancer J Clin
, vol.52
, Issue.3
, pp. 154-179
-
-
Hellerstedt, B.A.1
Pienta, K.J.2
-
10
-
-
10044276832
-
Management of androgen-independent prostate cancer
-
Epub 2004/12/31
-
Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control. 2004;11(6):364-73. Epub 2004/12/31.
-
(2004)
Cancer Control
, vol.11
, Issue.6
, pp. 364-373
-
-
Diaz, M.1
Patterson, S.G.2
-
11
-
-
77957252670
-
Castration-resistant prostate cancer: Descriptive yet pejorative?
-
Epub 2010/06/16
-
Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol. 28(23):e408. Epub 2010/06/16.
-
J Clin Oncol
, vol.28
, Issue.23
-
-
Crawford, E.D.1
Petrylak, D.2
-
12
-
-
41949104346
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
-
Epub 2008/03/04
-
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-59. Epub 2008/03/04. http://dx.doi.org/10.1200/JCO.2007.12.4487.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
Morris, M.4
Sternberg, C.N.5
Carducci, M.A.6
-
13
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treat- ment: A randomised open-label trial
-
Epub 2010/10/05
-
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treat- ment: a randomised open-label trial. Lancet. 376(9747):1147-54. Epub 2010/10/05.
-
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
de Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
Hansen, S.4
Machiels, J.P.5
Kocak, I.6
-
14
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Epub 2010/09/08
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363(5):411-22. Epub 2010/09/08.
-
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
-
15
-
-
77951591066
-
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
-
Epub 2010/02/18
-
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 28(9):1496-501. Epub 2010/02/18.
-
J Clin Oncol
, vol.28
, Issue.9
, pp. 1496-1501
-
-
Danila, D.C.1
Morris, M.J.2
de Bono, J.S.3
Ryan, C.J.4
Denmeade, S.R.5
Smith, M.R.6
-
16
-
-
36849038314
-
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
-
Epub 2007/10/11
-
Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007;25(33):5313-8. Epub 2007/10/11. http://dx.doi.org/10.1200/JCO.2007.13.4536.
-
(2007)
J Clin Oncol
, vol.25
, Issue.33
, pp. 5313-5318
-
-
Basch, E.M.1
Somerfield, M.R.2
Beer, T.M.3
Carducci, M.A.4
Higano, C.S.5
Hussain, M.H.6
-
17
-
-
0031017228
-
Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
-
Epub 1997/01/01
-
Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15(1):382-8. Epub 1997/01/01.
-
(1997)
J Clin Oncol
, vol.15
, Issue.1
, pp. 382-388
-
-
Small, E.J.1
Vogelzang, N.J.2
-
18
-
-
33644675811
-
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
-
Epub 2005/11/10
-
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-61. Epub 2005/11/10. http://dx.doi.org/10.1200/JCO.2005.03.4777.
-
(2005)
J Clin Oncol
, vol.23
, Issue.32
, pp. 8253-8261
-
-
Scher, H.I.1
Sawyers, C.L.2
-
19
-
-
33749345244
-
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
-
Epub 2006/ 09/20
-
Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer. 2006;95(7):767-74. Epub 2006/ 09/20. http://dx.doi.org/10.1038/sj.bjc.6603223.
-
(2006)
Br J Cancer
, vol.95
, Issue.7
, pp. 767-774
-
-
Attard, G.1
Sarker, D.2
Reid, A.3
Molife, R.4
Parker, C.5
de Bono, J.S.6
-
20
-
-
0029011116
-
Mutation of the androgen-receptor gene in metastatic androgen- independent prostate cancer
-
Epub 1995/05/25
-
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen- independent prostate cancer. N Engl J Med. 1995;332(21):1393-8. Epub 1995/05/25. http://dx.doi.org/10.1056/NEJM199505253322101.
-
(1995)
N Engl J Med
, vol.332
, Issue.21
, pp. 1393-1398
-
-
Taplin, M.E.1
Bubley, G.J.2
Shuster, T.D.3
Frantz, M.E.4
Spooner, A.E.5
Ogata, G.K.6
-
21
-
-
1842457650
-
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
-
Epub 2004/03/17
-
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025-33. Epub 2004/03/17. http://dx.doi.org/10.1200/JCO.2004.06.037.
-
(2004)
J Clin Oncol
, vol.22
, Issue.6
, pp. 1025-1033
-
-
Small, E.J.1
Halabi, S.2
Dawson, N.A.3
Stadler, W.M.4
Rini, B.I.5
Picus, J.6
-
22
-
-
1842829888
-
The patient with hormone-refractory prostate cancer: Determining who, when, and how to treat
-
Epub 2004/01/30
-
Kent EC, Hussain MH. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology. 2003;62 Suppl 1:134-40. Epub 2004/01/30. http://dx.doi.org/10.1016/j.urology.2003.09.005.
-
(2003)
Urology
, vol.62
, Issue.SUPPL.
, pp. 134-140
-
-
Kent, E.C.1
Hussain, M.H.2
-
23
-
-
33646047147
-
Changing perspectives of the role of chemotherapy in advanced prostate cancer
-
Epub, 2006/04/25
-
Burgess EF, Roth BJ. Changing perspectives of the role of chemotherapy in advanced prostate cancer. Urol Clin North Am. 2006;33(2):227-36, vii. Epub 2006/04/25. http://dx.doi.org/10.1016/j.ucl.2005.12.006.
-
(2006)
Urol Clin North Am
, vol.33
, Issue.2
, pp. 227-236
-
-
Burgess, E.F.1
Roth, B.J.2
-
24
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Epub 2004/10/08
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12. Epub 2004/10/08. http://dx.doi.org/10.1056/NEJMoa040720.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
-
25
-
-
66349137641
-
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
-
Epub 2009/04/22
-
Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27(15):2450-6. Epub 2009/04/22. http://dx.doi.org/10.1200/JCO.2008.19.9810.
-
(2009)
J Clin Oncol
, vol.27
, Issue.15
, pp. 2450-2456
-
-
Hussain, M.1
Goldman, B.2
Tangen, C.3
Higano, C.S.4
Petrylak, D.P.5
Wilding, G.6
-
26
-
-
0021796372
-
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
-
Epub 1985/06/01
-
Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985;3(6):827-41. Epub 1985/06/01.
-
(1985)
J Clin Oncol
, vol.3
, Issue.6
, pp. 827-841
-
-
Eisenberger, M.A.1
Simon, R.2
O'Dwyer, P.J.3
Wittes, R.E.4
Friedman, M.A.5
-
27
-
-
0027532535
-
Cytotoxic chemotherapy for advanced hormone- resistant prostate cancer
-
Epub 1993/02/01
-
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone- resistant prostate cancer. Cancer. 1993;71(3 Suppl):1098-109. Epub 1993/02/01. http://dx.doi.org/10.1002/1097-0142(19930201)71:3+,1098::AID-CNCR2820711432.3.0.CO;2-G.
-
(1993)
Cancer
, vol.71
, Issue.3 SUPPL.
, pp. 1098-1109
-
-
Yagoda, A.1
Petrylak, D.2
-
28
-
-
0030997896
-
Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer
-
Epub 1997/04/01
-
Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer. 1997;33(4):566-74. Epub 1997/04/01. http://dx.doi.org/10.1016/S0959-8049(96)00510-2.
-
(1997)
Eur J Cancer
, vol.33
, Issue.4
, pp. 566-574
-
-
Raghavan, D.1
Koczwara, B.2
Javle, M.3
-
29
-
-
0030459521
-
Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer
-
Epub 1996/01/01
-
Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. 1996;14(6):513-7. Epub 1996/01/01. http://dx.doi.org/10.3109/07357909609076896.
-
(1996)
Cancer Invest
, vol.14
, Issue.6
, pp. 513-517
-
-
Figg, W.D.1
Ammerman, K.2
Patronas, N.3
Steinberg, S.M.4
Walls, R.G.5
Dawson, N.6
-
30
-
-
0027511899
-
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
-
Epub 1993/04/01
-
Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11(4):607-15. Epub 1993/04/01.
-
(1993)
J Clin Oncol
, vol.11
, Issue.4
, pp. 607-615
-
-
Kelly, W.K.1
Scher, H.I.2
Mazumdar, M.3
Vlamis, V.4
Schwartz, M.5
Fossa, S.D.6
-
31
-
-
0032747375
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
-
Epub 1999/11/05
-
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461-7. Epub 1999/11/05.
-
(1999)
J Clin Oncol
, vol.17
, Issue.11
, pp. 3461-3467
-
-
Bubley, G.J.1
Carducci, M.2
Dahut, W.3
Dawson, N.4
Daliani, D.5
Eisenberger, M.6
-
32
-
-
24944582166
-
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
-
Epub 2005/09/02
-
Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23(25):6139-48. Epub 2005/09/02.
-
(2005)
J Clin Oncol
, vol.23
, Issue.25
, pp. 6139-6148
-
-
Collette, L.1
Burzykowski, T.2
Carroll, K.J.3
Newling, D.4
Morris, T.5
Schroder, F.H.6
-
33
-
-
34548537940
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
-
Epub 2007/09/01
-
Armstrong AJ, Garrett-Mayer E, Yang YC, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965-70. Epub 2007/09/01. http://dx.doi.org/10.1200/JCO.2007.11.4769.
-
(2007)
J Clin Oncol
, vol.25
, Issue.25
, pp. 3965-3970
-
-
Armstrong, A.J.1
Garrett-Mayer, E.2
Yang, Y.C.3
Carducci, M.A.4
Tannock, I.5
de Wit, R.6
-
34
-
-
0036789479
-
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
-
Epub 2002/09/28
-
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972-82. Epub 2002/09/28. http://dx.doi.org/10.1200/JCO.2002.11.021.
-
(2002)
J Clin Oncol
, vol.20
, Issue.19
, pp. 3972-3982
-
-
Smaletz, O.1
Scher, H.I.2
Small, E.J.3
Verbel, D.A.4
McMillan, A.5
Regan, K.6
-
35
-
-
0032886933
-
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
-
Epub 1999/10/03
-
Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;17(10):3160-6. Epub 1999/10/03.
-
(1999)
J Clin Oncol
, vol.17
, Issue.10
, pp. 3160-3166
-
-
Hudes, G.1
Einhorn, L.2
Ross, E.3
Balsham, A.4
Loehrer, P.5
Ramsey, H.6
-
36
-
-
10744221004
-
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
-
Epub 2004/01/08
-
Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer. 2004;90(1):100-5. Epub 2004/01/08.
-
(2004)
Br J Cancer
, vol.90
, Issue.1
, pp. 100-105
-
-
Albrecht, W.1
van Poppel, H.2
Horenblas, S.3
Mickisch, G.4
Horwich, A.5
Serretta, V.6
-
37
-
-
0021085751
-
Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer
-
Epub 1983/12/01
-
Osborne CK, Drelichman A, Von Hoff DD, Crawford ED. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983;67(12):1133-5. Epub 1983/12/01.
-
(1983)
Cancer Treat Rep
, vol.67
, Issue.12
, pp. 1133-1135
-
-
Osborne, C.K.1
Drelichman, A.2
von Hoff, D.D.3
Crawford, E.D.4
-
38
-
-
0024535895
-
Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
-
Epub 1989/05/01
-
Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7(5):590-7. Epub 1989/05/01.
-
(1989)
J Clin Oncol
, vol.7
, Issue.5
, pp. 590-597
-
-
Tannock, I.1
Gospodarowicz, M.2
Meakin, W.3
Panzarella, T.4
Stewart, L.5
Rider, W.6
-
39
-
-
8944220720
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian rando- mized trial with palliative end points
-
Epub 1996/06/01
-
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian rando- mized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-64. Epub 1996/06/01.
-
(1996)
J Clin Oncol
, vol.14
, Issue.6
, pp. 1756-1764
-
-
Tannock, I.F.1
Osoba, D.2
Stockler, M.R.3
Ernst, D.S.4
Neville, A.J.5
Moore, M.J.6
-
40
-
-
0032784113
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
-
Epub 1999/11/24
-
Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-13. Epub 1999/11/24.
-
(1999)
J Clin Oncol
, vol.17
, Issue.8
, pp. 2506-2513
-
-
Kantoff, P.W.1
Halabi, S.2
Conaway, M.3
Picus, J.4
Kirshner, J.5
Hars, V.6
-
41
-
-
0036895169
-
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
-
Epub 2002/11/21
-
Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168(6):2439-43. Epub 2002/11/21.
-
(2002)
J Urol
, vol.168
, Issue.6
, pp. 2439-2443
-
-
Berry, W.1
Dakhil, S.2
Modiano, M.3
Gregurich, M.4
Asmar, L.5
-
42
-
-
0034772296
-
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
-
Epub 2001/11/08
-
Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12(9):1273-9. Epub 2001/11/08,
-
(2001)
Ann Oncol
, vol.12
, Issue.9
, pp. 1273-1279
-
-
Beer, T.M.1
Pierce, W.C.2
Lowe, B.A.3
Henner, W.D.4
-
43
-
-
0034789841
-
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate
-
Epub 2001/ 10/31
-
Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28(4 Suppl 15):8-15. Epub 2001/ 10/31. http://dx.doi.org/10.1016/S0093-7754(01)90149-6.
-
(2001)
Semin Oncol
, vol.28
, Issue.4-15 SUPPL.
, pp. 8-15
-
-
Berry, W.1
Dakhil, S.2
Gregurich, M.A.3
Asmar, L.4
-
44
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Epub 2004/10/08
-
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20. Epub 2004/10/08. http://dx.doi.org/10.1056/NEJMoa41318.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
-
45
-
-
0038415813
-
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats
-
Epub 2003/04/25
-
Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol. 2003;138(7):1367-75. Epub 2003/04/25. http://dx.doi.org/10.1038/sj.bjp.0705150.
-
(2003)
Br J Pharmacol
, vol.138
, Issue.7
, pp. 1367-1375
-
-
Cisternino, S.1
Bourasset, F.2
Archimbaud, Y.3
Semiond, D.4
Sanderink, G.5
Scherrmann, J.M.6
-
46
-
-
59449102526
-
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
-
Epub 2009/ 01/17
-
Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723-30. Epub 2009/ 01/17. http://dx.doi.org/10.1158/1078-0432.CCR-08-0596.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.2
, pp. 723-730
-
-
Mita, A.C.1
Denis, L.J.2
Rowinsky, E.K.3
Debono, J.S.4
Goetz, A.D.5
Ochoa, L.6
-
47
-
-
0038052594
-
Preclinical evaluation of TXD258, a novel taxoid
-
abstract
-
Bissery C, Bouchard H, Riou JF, Vrignaud P, Combeau C, Bourzat JD, et al. Preclinical evaluation of TXD258, a novel taxoid. Proc Am Assoc Cancer Res. 2000;41: abstract 1364.
-
(2000)
Proc Am Assoc Cancer Res
, vol.41
-
-
Bissery, C.1
Bouchard, H.2
Riou, J.F.3
Vrignaud, P.4
Combeau, C.5
Bourzat, J.D.6
-
48
-
-
50849088935
-
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
-
Epub 2008/04/26
-
Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547-52. Epub 2008/04/26.
-
(2008)
Ann Oncol
, vol.19
, Issue.9
, pp. 1547-1552
-
-
Pivot, X.1
Koralewski, P.2
Hidalgo, J.L.3
Chan, A.4
Goncalves, A.5
Schwartsmann, G.6
-
49
-
-
53749090666
-
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
-
Epub 2008/07/23
-
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71. Epub 2008/07/23. http://dx.doi.org/10.1200/JCO.2007.15.9749.
-
(2008)
J Clin Oncol
, vol.26
, Issue.28
, pp. 4563-4571
-
-
Attard, G.1
Reid, A.H.2
Yap, T.A.3
Raynaud, F.4
Dowsett, M.5
Settatree, S.6
-
50
-
-
68949094223
-
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
-
Epub 2009/05/28
-
Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27(23):3742-8. Epub 2009/05/28. http://dx.doi.org/10.1200/JCO.2008.20.0642.
-
(2009)
J Clin Oncol
, vol.27
, Issue.23
, pp. 3742-3748
-
-
Attard, G.1
Reid, A.H.2
A'Hern, R.3
Parker, C.4
Oommen, N.B.5
Folkerd, E.6
-
51
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
Epub 2011/05/27
-
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364(21):1995-2005. Epub 2011/05/27.
-
N Engl J Med
, vol.364
, Issue.21
, pp. 1995-2005
-
-
de Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
Fizazi, K.4
North, S.5
Chu, L.6
-
52
-
-
68549135290
-
Integrated data from 2 randomized, double-blind, placebocontrolled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
-
Epub 2009/06/19
-
Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebocontrolled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-9. Epub 2009/06/19. http://dx.doi.org/10.1002/cncr.24429.
-
(2009)
Cancer
, vol.115
, Issue.16
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
Burch, P.A.4
Nemunaitis, J.5
Yuh, L.6
-
53
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Epub 2010/04/20
-
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 375(9724):1437-46. Epub 2010/04/20.
-
Lancet
, vol.375
, Issue.9724
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
Anand, A.4
Taplin, M.E.5
Efstathiou, E.6
-
54
-
-
77955714649
-
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, predni- sone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
-
abstr LBA4511
-
Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, predni- sone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA4511).
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Kelly, W.K.1
Halabi, S.2
Carducci, M.A.3
George, D.J.4
Mahoney, J.F.5
Stadler, W.M.6
-
55
-
-
0037303436
-
Targeting prostate cancer bone metastases
-
Epub 2003/01/28
-
Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer. 2003;97(3 Suppl):785-8. Epub 2003/01/28. http://dx.doi.org/10.1002/cncr.11130.
-
(2003)
Cancer
, vol.97
, Issue.3 SUPPL.
, pp. 785-788
-
-
Logothetis, C.1
Tu, S.M.2
Navone, N.3
-
56
-
-
41849083088
-
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases
-
Epub 2007/12/12
-
Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int. 2008;101(9):1071-5. Epub 2007/12/12. http://dx.doi.org/10.1111/j.1464-410X.2007.07364.x.
-
(2008)
BJU Int
, vol.101
, Issue.9
, pp. 1071-1075
-
-
Saad, F.1
Markus, R.2
Goessl, C.3
-
57
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
Epub 2004/06/03
-
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute. 2004;96(11):879-82. Epub 2004/06/03.
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.11
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
Tchekmedyian, S.4
Venner, P.5
Lacombe, L.6
-
58
-
-
0035798930
-
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial
-
Epub 2001/02/24
-
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336-41. Epub 2001/02/24. http://dx.doi.org/10.1016/S0140-6736(00)03639-4.
-
(2001)
Lancet
, vol.357
, Issue.9253
, pp. 336-341
-
-
Tu, S.M.1
Millikan, R.E.2
Mengistu, B.3
Delpassand, E.S.4
Amato, R.J.5
Pagliaro, L.C.6
-
59
-
-
78349290889
-
A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
-
abstr LBA4507
-
Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA4507).
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Fizazi, K.1
Carducci, M.A.2
Smith, M.R.3
Damião, R.4
Brown, J.E.5
Karsh, L.6
-
60
-
-
66349100456
-
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
-
Epub 2009/04/15
-
Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436-42. Epub 2009/04/15. http://dx.doi.org/10.1200/JCO.2008.20.4164.
-
(2009)
J Clin Oncol
, vol.27
, Issue.15
, pp. 2436-2442
-
-
Morris, M.J.1
Pandit-Taskar, N.2
Carrasquillo, J.3
Divgi, C.R.4
Slovin, S.5
Kelly, W.K.6
-
61
-
-
0029085123
-
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
-
Epub 1995/09/01
-
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1(9):944-9. Epub 1995/09/01. http://dx.doi.org/10.1038/nm0995-944.
-
(1995)
Nat Med
, vol.1
, Issue.9
, pp. 944-949
-
-
Nelson, J.B.1
Hedican, S.P.2
George, D.J.3
Reddi, A.H.4
Piantadosi, S.5
Eisenberger, M.A.6
-
62
-
-
77951462234
-
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer
-
Epub 2010/02/19
-
Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 116(9):2132-9. Epub 2010/02/19.
-
Cancer
, vol.116
, Issue.9
, pp. 2132-2139
-
-
Chadha, M.K.1
Tian, L.2
Mashtare, T.3
Payne, V.4
Silliman, C.5
Levine, E.6
-
63
-
-
62649134676
-
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double- blind, placebo-controlled, randomised, phase 2 trial
-
Epub 2008/12/02
-
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double- blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009;55(5):1112-23. Epub 2008/12/02. http://dx.doi.org/10.1016/j.eururo.2008.11.002.
-
(2009)
Eur Urol
, vol.55
, Issue.5
, pp. 1112-1123
-
-
James, N.D.1
Caty, A.2
Borre, M.3
Zonnenberg, B.A.4
Beuzeboc, P.5
Morris, T.6
-
64
-
-
79955068371
-
Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial
-
abstr 4509
-
Scher HI, Chi KN, De Wit R, Berry WR, Albers P, Henick B, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. J Clin Oncol 28:15s (suppl; abstr 4509). 2010.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Scher, H.I.1
Chi, K.N.2
de Wit, R.3
Berry, W.R.4
Albers, P.5
Henick, B.6
|